TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Co-Infection
Reports from P.J. Munseri and co-researchers add new data to research in HIV/AIDS co-infection
October 14th, 2008
According to recent research from Lebanon, "Isoniazid preventive therapy (IPT) has not been widely implemented due to questions about acceptance, adherence and side effects. To examine factors related to completion of IPT among human immunodeficiency virus (HIV) infected subjects in Tanzania." "HIV-infected subjects in the DarDar TB vaccine trial with CD4 cell counts >= 200 cells/mm(3) and a positive tuberculin skin test (TST) were counseled, offered IPT for 6 months and seen monthly. Among 1932 subjects, TST results were positive in 631 (33%): 568 (90%) were offered IPT, 565 (99%) accepted and three (< 1%) refused. Of the 565 subjects who accepted IPT, 493 (87%)...
Source: TB & Outbreaks Week (2008-10-14)
|
